Rare diseases
Investigational molecules
Locations
Novo Alle 1, 2880, Denmark
Extensive work in type 2 diabetes and type 1 diabetes, with attention to blood glucose control, treatment intensification, and combinations involving basal insulin, GLP-1 receptor agonists, and SGLT2 inhibitors. Research also includes paediatric type 2 diabetes and diabetes-related complications.
Clinical interest extends to metabolic control across age groups, including adolescents and children, with studies touching on diabetes management alongside excess body weight.
Novo Nordisk A/S runs clinical trials in conditions such as Obesity, Type 2 diabetes mellitus, Overweight, Sickle cell disease, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease
BulgariaZenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
BulgariaA study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis
BulgariaA study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis
BulgariaEfficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes
GermanyEfficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity
BelgiumStudy comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity
GreeceA Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes
CroatiaZenagamtide for Weight Loss in Adults with Obesity
BelgiumA study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity
AustriaStudy of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
BulgariaA study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure
DenmarkIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
